Skip to main content

Table 4 Reasons for non-compliance with SOGUG guidelines

From: Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

  Sunitinib
718
Sorafenib
227
Pazopanib
142
Everolimus
166
Temsirolimus
100
Bevacizumab
21
Hypertension, n cycles (%) 374 227 73 3
 Basal BP not recorded 226 (99.6) 27 (37.0) 3 (100)
 BP not recorded 363 (97.1) 137 (60.4) 45 (61.6)
 Dose reduction 9 (2.4) 1 (1.4)
 Dose interruption 1 (0.3)
 Treatment discontinuation 2 (0.5) 1 (0.4)
Cardiac toxicity, n cycles (%) 518
 Non-recorded basal LVEF 145 (28.0)
 LVEF not performed 484 (93.4)
 Dose reduction 1 (0.2)
 Dose interruption 1 (0.2)
 Treatment discontinuation 2 (0.4)
Hypotyroidism, n cycles (%) 389
 Basal TSH not recorded 114 (29.3)
 TSH > 10 mU/l not-performed 358 (92.0)
 Dose interruption 2 (0.5)
Diarrhea, n cycles (%) 180 31 36
 Not recorded 165 (91.7) 29 (93.5) 36 (100)
 Dose reduction 12 (6.7) 1 (3.2)
 Dose interruption 3 (1.7) 1 (3.2)
Hyperglycemia, n cycles (%) 50 33
 Not recorded 25 (100) 33 (100)
Dyslipemia, n cycles (%) 102 72
 Not recorded 102 (100) 72 (100)
Pneumonitis, n cycles (%) 71 37
 Basal data not recorded 66 (93.0) 35 (94.6)
 Follow-up data not recorded 5 (7.0) 1 (2.7)
 Treatment discontinuation 2 (2.8) 1 (2.7)
Liver toxicity, n cycles (%) 104
 Basal liver function not recorded 19 (18.3)
 Liver function not recorded 81 (77.9)
 ALT increase > 3–8 ULN 5 (4.8)
 Dose interruption 2 (1.9)
 Treatment discontinuation 1 (1.0)
Proteinuria, n cycles (%)  
Not performed 19 (100)
  1. Length of cycles according to routine clinical practice: sunitinib 6 weeks; other treatments 4 weeks